



Consiglio Nazionale delle Ricerche
Istituto di Biostrutture e Bioimmagini



Al Direttore della Stazione Appaltante
Dott. Marcello Mancini
c/o sede

Oggetto DICHIARAZIONE DI ACCETTAZIONE DELL'INCARICO E DI ASSENZA DI CAUSE DI INCOMPATIBILITÀ E DI ASTENSIONE PER LA NOMINA A COMPONENTE DELLA COMMISSIONE GIUDICATRICE PER LA PROCEDURA SOTTO SOGLIA COMUNITARIA AI SENSI DELL'ART. 36 COMMA 2, LETT. B) DEL D. LGS N. 50/2016 E S.M.I. PER L'AFFIDAMENTO DELL'APPALTO AVENTE AD OGGETTO LA FORNITURA ED INSTALLAZIONE DI STRUMENTI SCIENTIFICI CPV 38430000-8, POR CAMPANIA FESR 2014-2020 DAL TITOLO "CIRO CAMPANIA IMAGING INFRASTRUCTURE FOR RESEARCH IN ONCOLOGY. CUP: B61G17000190007 - LOTTO 1 CIG: 8764919FF5

Il sottoscritto MENOTTI RUVO, nato ad AVELLINO, il 20/04/1964, con riferimento alla gara di cui in oggetto ed a seguito della comunicazione inviata dal RUP contenente l'intenzione di codesta Direzione di procedere alla nomina quale componente effettivo della Commissione giudicatrice, consapevole della responsabilità e delle conseguenze civili e penali previste in casi di rilascio di dichiarazioni mendaci e/o formazione di atti falsi e/o uso degli stessi, ai sensi e per gli effetti dell'art. 76 del D.P.R. n. 445/2000,

DICHIARA

- 1) Di accettare l'incarico di cui trattasi;
- 2) Di uniformarsi ai principi contenuti nel "Codice di comportamento dei dipendenti delle Pubbliche Amministrazioni" (di cui D.P.R. 16/4/2013, n. 62 - pubblicato nella Gazzetta Ufficiale 4 giugno 2013, n. 129, in vigore dal 19 giugno 2013) nonché nel vigente "Codice di comportamento dei dipendenti CNR ai sensi dell'art. 54, comma 5, D. Lgs. 165/2001;
- 3) Di prendere atto che hanno presentato offerta i sottonotati operatori economici:
 - Operatore economico Thermo Fisher Scientific spa con sede legale ed operativa in Rodano (MI), Strada Rivoltana KM 4, C.a.p. 20090 Codice Fiscale e Partita IVA: 07817950152;
- 4) L'assenza di conflitto di interesse di cui all'art. 42 comma 2 del D. Lgs. 50/2016 e s.m.i.;
- 5) L'assenza delle cause di incompatibilità e di astensione di cui all'art. 77, commi 4, 5 e 6 del D. Lgs. 50/2016 e s.m.i.;

Allega alla presente il proprio curriculum vitae nonché copia di un documento di identità in corso di validità, nel caso di sottoscrizione con firma autografa.

NAPOLI, 20 SETTEMBRE 2021

Firma

Sede istituzionale: Via Tommaso De Amicis, 95 / 80145 Napoli (NA) - Tel. 081 2203401 / Fax: 081 2203498

Sedi secondarie: NAPOLI - Via Mezzocannone, 16 / 80134 - Tel. 081 2532039 | TORINO - Via Nizza, 52 / 10126 - Tel. 011 633448

Codice fiscale: 80054330586 - Partita Iva: 02118311006 / pec: protocollo.ibb@pec.cnr.it / email: segreteria.direzione@ibb.cnr.it / website: www.ibb.cnr.it

PERSONAL INFORMATION

Family name, First name: **Ruvo, Menotti**

Researcher unique identifier(s): **Researcher ID: K-2603-2018; Scopus Author ID: 6602155654; ORCID: 0000-0001-5997-756X.**

Date of birth: **April, 20th, 1964.**

Nationality: **Italian**

URL for web site: **<http://www.ibb.cnr.it/?command=viewu&id=386>**

• EDUCATION

1991 Master degree, Department of Chemistry, University of Napoli, Federico II, Italy.

• CURRENT POSITION(S)

2020 –Current Position: Research Director, IBB, CNR, Napoli.

• PREVIOUS POSITIONS

2001-2001 Position held: Associate Director, Xeptagen SpA, Napoli

1991 – 2000 Position held: Senior Scientist, Tecnogen SpA, Caserta

• ORGANISATION OF SCIENTIFIC MEETINGS (if applicable)

2014, Co-chairman 14th Naples Workshop on Bioactive Peptides; Country: Italy (Naples).

2016, Co-chairman 15th Naples Workshop on Bioactive Peptides; Country: Italy (Naples).

2018, Co-chairman 16th Naples Workshop on Bioactive Peptides; Country: Italy (Naples).

2007, Organizing committee, First Symposium on Combinatorial Science in Biology, Chemistry, Catalysts and Materials. Italy (Florence)

• REVIEWING ACTIVITIES (if applicable)

2019-present: Editor and reviewer: International Journal of Molecular Sciences, MDPI
Academic Editor

2019-present: Editor and reviewer: Scientific Report, Springer. Academic Editor

2020-present: Editor and reviewer: Current Pharmaceutical Biotechnologies, Bentham
Academic Editor.

2013-present: Editor and reviewer: Current Drug Discovery technologies, Bentham

Academic Editor. Protein and Peptide Letter, Bentham. Academic Editor.

Evaluator for FET-OPEN projects (2020), FP VII projects (2011); ANF (2017); PRIN, FIRB,

Scientific Cooperation Between Germany And Israel (Israel), Rustaveli Foundation (Georgia), ESF
EUROCORES, European Association for Haemophilia and Allied Disorders.

• MEMBERSHIPS OF SCIENTIFIC SOCIETIES (if applicable)

2017 – present Founding Member, Research Network Italian Peptide Network.

2004 –2012 Associated Member: European Peptide Society

2004 – 2009 Associated Member: American Peptide Society

Appendix: All ongoing and submitted grants and funding of the PI and of the Team Members (Funding ID)

On-going Grants (Please indicate "No funding" when applicable):

<i>Project Title</i>	<i>Funding source</i>	<i>Amount (Euros)</i>	<i>Period</i>	<i>Role of PI or Team Member</i>	<i>Relation to current proposal</i>
NEON - ARS01_00769	MUR	438.000 (IBB-CNR amount)	April 2019 – December 2022	PI for IBB-CNR	The project aims at developing new CMOS- and Lab-on-fiber devices for detecting biomarkers for cancer and neurodegenerative diseases. IBB-CNR contributes by choosing and validating the bioreceptors needed for analyte's capture and by setting up the immobilization conditions on the sensor's surface.
NANOCAN, Progetti Oncologia	Regione Campania	180.000 euro (IBB-CNR amount as member of the CERICT consortium)	January 2018 – December 2022	PI for IBB-CNR	The project aims at developing Lab-on-fiber devices for detecting new biomarkers for cancer diseases. IBB-CNR contributes by choosing and validating the bioreceptors needed for analyte's capture and by setting up the immobilization conditions on the sensor's surface.
OPTIMA, FESR	Regione Campania	120.000 euro (IBB-CNR amount as member of the TOP-IN consortium)	January 2016 – November 2020.	PI for IBB-CNR	The project aimed at developing Lab-on-fiber devices for detecting Vitamin D in blood samples. IBB-CNR contributed by choosing and validating the bioreceptors and by immobilizing them on the sensor's surface.
PRIN: – Bando 2015 Prot. 2015783 N45_03	MUR	80.000 euro (IBB-CNR amount)	February 2017 – February 2020	PI for IBB-CNR	The project aimed at developing Lab-on-fiber devices for detecting miRNA in blood samples as biomarkers for neurodegenerative diseases. IBB-CNR contributed by choosing and validating the bioreceptors and by immobilizing them on the sensor's surface.
PROGETTO SANITÀ	MiSA	160.000 euro (IBB-CNR amount)	November 2019 – April 2022	PI for IBB-CNR	The project aims at studying new CAR-T based therapies. IBB-CNR contributes by preparing and studying new scFv against cancer antigens.

Grant applications (Please indicate "No funding" when applicable):

<i>Project Title</i>	<i>Funding source</i>	<i>Amount (Euros)</i>	<i>Period</i>	<i>Role of PI or Team Member</i>	<i>Relation to current proposal</i>
FET OPEN	EU	80.000 euro	2020- Not funded	PI for IBB-CNR	Compact, fully autonomous, optical point-of-care system for Covid.

PRIN_2017MWLEK2	MUR	100.000 euro	2017-Not funded	PI for IBB-CNR	Multiplexed on-bead photonic devices for detecting Thyreoglobulin in blood samples
PRIN_2020239LYL	MUR	450.000 euro	2021-Awaiting review	PI	Multiplexed on-bead photonic devices for detecting prostate cancer biomarkers in blood samples.

Ten years track-record (max. 2 pages)

Dr. M. Ruvo has been Senior Scientist (Primo Ricercatore) at the Institute of Biostructure and Bioimaging of CNR (IBB-CNR) from January 2002 up to January 2020. Since January 2020 he is Research Director (Dirigente di Ricerca) at the same institute. Before joining the CNR, he has been Junior Scientist (1991-1993), Senior Scientist (1993-2001) and finally Associate Director (2001) in pharmaceutical companies. He holds a degree in Chemistry obtained at the University of Napoli Federico II and has a background in protein chemistry and biochemistry and in peptide chemistry. He has developed skills in the development of bioactive peptides, recombinant proteins, monoclonal antibodies and antibody fragments utilized as new potential biotherapeutics and diagnostics. He has also an expertise in developing new reagents and assays for detecting biomarkers and contributed to the development of new optical fiber-based label-free devices (Giaquinto, et al., ACS Photonics, 2019, 6, 12, 3271–3280; patent n° WO2017IB52533). He has contributed to develop up to the pre-clinical and clinical phases several bioactive peptides against therapeutic targets for oncology (DTP3, patents WO2012GB50947, WO2010GB01970, clinical trial Phase 1/2a, patents licensed to Kesios Ltd; iVR1, patents WO20053773, WO20053772, preclinical, patents licenced to Anbition srl; CBP, patent EP20090166967, pre-clinical), eye diseases (iVR1, patents W O20053773, WO 20053772, preclinical, patents licenced to Anbition srl) and cardiovascular diseases, (AIF 370-394, pre-clinical; Chelko, et al., (2021) Science Translational Medicine, 13 (581), art. no. eabf0891, patent n° US Patent App. 63/147,068, patent licensed to John Hopkins University). He has been one of the founding members of Almabs srl, (2009, terminated 2012), Kesios Therapeutics Ltd (2012) and Anbition srl (2018), the last two companies are still operative. He has contributed to develop monoclonal antibodies against protein targets like Cripto-1 (Focà, et al., (2019) Biochimie, 158, pp. 246-256), Nodal (patent n° WO2015US54515, licensed to Tai-Rx, Taiwan). In the last 10 years at the IBB-CNR, he has published 115 papers in international peer-reviewed journals (Scopus.com) with a 10-years H-Index of 17. He is co-inventor of 10+ different patents, three of which have been licenced to companies (see above). In the last 10 years he has been Principal Investigator for some 20 different funded projects – five of which in the field of new biosensor's development - and received financial support for around 4.7 million euros. In the same period he has been supervisor of at least 15 different graduated and post-doc fellows supported by projects in different areas; he has been supervisors of at least 20 master and PhD students. He has served and serves as consultant for several companies, including Kesios Therapeutics, (2014-2015), Bracco Imaging (2016-2017) and BIOVIIIx (2019-present).

Publications

Please, indicate the total n. publications, the H-Index, the averaged IF and the top publications of the last 10 years (no page limits max. 15 publications)

Source: www.scopus.com

H-Index: 29.

N. Publication: 162.

Average IF: 5.

1 - Giaquinto, M., Aliberti, A., Micco, A., Gambino, F., Ruvo, M., Ricciardi, A., Cusano, A.; Cavity-Enhanced Lab-on-Fiber Technology: Toward Advanced Biosensors and Nano-Opto-Mechanical Active Devices (2019) ACS Photonics, 6 (12), pp. 3271-3280.

2 - Scherino, L., Giaquinto, M., Micco, A., Aliberti, A., Bobeico, E., La Ferrara, V., Ruvo, M., Ricciardi, A., Cusano, A.; A time-efficient dip coating technique for the deposition of microgels onto the optical fiber tip (2018) Fibers, 6 (4), art. no. 72,

3 - Giaquinto, M., Ricciardi, A., Aliberti, A., Micco, A., Bobeico, E., Ruvo, M., Cusano, A.; Light-microgel interaction in resonant nanostructures (2018) Scientific Reports, 8 (1), art. no. 9331,

4 - Aliberti, A., Ricciardi, A., Giaquinto, M., Micco, A., Bobeico, E., La Ferrara, V., Ruvo, M., Cutolo, A., Cusano, A.; Microgel assisted Lab-on-Fiber Optrode (2017) Scientific Reports, 7 (1), art. no. 14459,

5 - Aliberti, A., Vaiano, P., Caporale, A., Consales, M., Ruvo, M., Cusano, A.; Fluorescent chemosensors for Hg²⁺ detection in aqueous environment (2017) Sensors and Actuators, B: Chemical, 247, pp. 727-735.

6 - Pilla, P., Sandomenico, A., Malachovská, V., Borriello, A., Giordano, M., Cutolo, A., Ruvo, M., Cusano, A.; A protein-based biointerfacing route toward label-free immunoassays with long period gratings in transition mode (2012) Biosensors and Bioelectronics, 31 (1), pp. 486-491.

7 - Giaquinto M, Micco A, Aliberti A, Bobeico E, La Ferrara V, Ruvo M, Ricciardi A, Cusano A. Optimization Strategies for Responsivity Control of Microgel Assisted Lab-On-Fiber Optrodes (2018). Sensors (Basel). Apr 6;18(4):1119.

8 - Quero G, Consales M, Severino R, Vaiano P, Boniello A, Sandomenico A, Ruvo M, Borriello A, Diodato L, Zuppolini S, Giordano M, Nettore IC, Mazzarella C, Colao A, Macchia PE, Santorelli F, Cutolo A, Cusano A. Long period fiber grating nano-optrode for cancer biomarker detection (2016). Biosens Bioelectron. Jun 15;80:590-600.

9 - Cusano, A.M., Aliberti, A., Cusano, A., Ruvo, M.; Detection of small DNA fragments by biolayer interferometry (2020) Analytical Biochemistry, 607, art. no. 113898.

10 - Di Meo V, Caporale A, Crescitelli A, Jannehc M, Palangec E, De Marcellis A, Portaccio M, Lepore M, Rendina I, Ruvo M, Esposito E. Metasurface based on cross-shaped plasmonic nanoantennas as chemical sensor for surface-enhanced infrared absorption spectroscopy. (2019) Sensors and Actuators B: Chemical Volume 286, Pages 600-607.

11 - Sivaccumar J, Sandomenico A, Vitagliano L, Ruvo M. Monoclonal Antibodies: A Prospective and Retrospective View (2021). Curr Med Chem.;28(3):435-471


12 - Sandomenico A, Focà A, Sanguigno L, Caporale A, Focà G, Pignalosa A, Corvino G, Caragnano A, Beltrami AP, Antoniali G, Tell G, Leonardi A, Ruvo M. Monoclonal antibodies against pools of mono- and polyacetylated peptides selectively recognize acetylated lysines within the context of the original antigen (2016). MAbs. Nov/Dec;8(8):1575-1589.

13 - Selis F, Sandomenico A, Cantile M, Sanna R, Calvanese L, Falcigno L, Dell'Omo P, Esperti A, De Falco S, Focà A, Caporale A, Iaccarino E, Truppo E, Scaramuzza S, Tonon G, Ruvo M. Generation and testing of engineered multimeric Fabs of trastuzumab (2020). Int J Biol Macromol. Dec 1;164:4516-4531.

14 - Sandomenico A, Leonardi A, Berisio R, Sanguigno L, Focà G, Focà A, Ruggiero A, Doti N, Muscariello L, Barone D, Farina C, Owsianka A, Vitagliano L, Patel AH, Ruvo M. Generation and Characterization of Monoclonal Antibodies against a Cyclic Variant of Hepatitis C Virus E2 Epitope 412-422 (2016). J Virol. Jan 27;90(7):3745-59.

15 - Tornatore, L., Sandomenico, A., Raimondo, D., ...Ruvo, M., Franzoso, G. Cancer-Selective Targeting of the NF- κ B Survival Pathway with GADD45 β /MKK7 Inhibitors (2014). Cancer Cell, 26(6), pp. 938.

Scadenza : 20-04-2024
Diritti : 5,50



AU 7238490

IPZS - Roma - D.C.V. - ROMA

REPUBBLICA ITALIANA



COMUNE DI
SAN NICOLA LA STRADA

CARTA D'IDENTITA'

N° AU 7238490

DI
RUVO MENOTTI

Cognome RUVO
Nome MENOTTI
nato il 20-04-1964
(atto n. 685 P. 1 S. A 1964)
a AVELLINO
a ITALIANA
Cittadinanza SAN NICOLA LA STRADA (CE)
Residenza FEDERICO FELLINI 11
Via STATO LIBERO
Stato civile CHIMICO
Professione

CONNOTATI E CONTRASSEGNI SALIENTI

Statura 177
Capelli Brizzolati
Occhi Castani
Segni particolari NESSUNO



Firma del titolare...
SAN NICOLA LA STRADA, 17-02-2014



IL SINDACO
UFFICIALE DI ANAGRAFE
LATTERO Anna Maria

